In a post hoc analysis of 210 ICU-admitted patients from the French multicenter COMBAT cohort, nearly half of survivors of community-acquired bacterial meningitis still had unfavourable functional outcomes 1 year after intensive care. Hearing loss, depressive symptoms, and impaired physical quality of life were common, while fewer than half resumed work. The SOFA score on day 3 independently predicted 30-day mortality, highlighting the value of repeated organ function assessment.
Surviving community-acquired bacterial meningitis often does not mean returning to normal life. In a French multicenter study published online in the Journal of Intensive Medicine on June 13, 2026, French intensivists found that nearly half of patients admitted to intensive care for bacterial meningitis still had significant functional impairment 1 year later—and fewer than one in two had resumed working.
Community-acquired adult bacterial meningitis (CABM) remains a rare but devastating infection, with reported mortality rates ranging from 9% to 30% in adults. Although most severe cases are admitted to an intensive care unit (ICU), data specifically describing the outcomes of these critically ill patients have remained scarce. Prior studies have focused either on the broader population or on short-term hospital outcomes, leaving a gap regarding what happens to ICU survivors months after discharge.
The team analysed data from 210 ICU-admitted adults enrolled in the prospective COMBAT cohort across 27 French ICUs between 2013 and 2015. Patients were followed for 12 months using a comprehensive battery of validated tools assessing neurological status (Glasgow Outcome Scale (GOS), modified Rankin Scale), psychological state (Center for Epidemiologic Studies Depression scale), quality of life (SF-12), hearing, and return to work—making it one of the most thorough long-term assessments of this population to date.
The results paint a sobering picture of life after ICU-treated meningitis. Twelve months after the admission, 51% of survivors had an unfavorable GOS score, hearing loss affected 31%, and 34% experienced clinically significant depressive symptoms. Half of the survivors reported impaired physical quality of life. Return to work was achieved by only 47% overall—and showed a striking age gradient: 79% in patients under 55 years of age, versus only 19% in older survivors.
On the acute side, the 30-day mortality rate reached 17%. Two factors independently predicted death within a month: the Sequential Organ Failure Assessment (SOFA) score at ICU admission, and notably the SOFA score on day 3. Each one-point increase in the day 3 score raised the odds of death by roughly 50%. This finding suggests that the trajectory of organ dysfunction during the first days in ICU may matter as much as severity at admission. Repeated, structured re-evaluation of organ function could help identify patients who might benefit from more aggressive interventions or earlier therapeutic reorientation.
The study also clarifies the role of the pathogen. Meningococcal meningitis ( Neisseria meningitidis ) was more than three times more likely to lead to ICU admission than other bacterial causes, yet meningococcal patients had better 30-day survival than those infected with Streptococcus pneumoniae and other organisms. This counterintuitive pattern probably reflects how clinical signs such as purpura prompt clinicians to admit patients rapidly to critical care— where the disease, although severe, often responds well to prompt antibiotic treatment.
The take-home message is twofold. Acutely, intensivists should integrate repeated SOFA assessment into prognostic reasoning beyond the first hours of admission. In the longer term, the burden of post-meningitis sequelae—neurological, psychological, sensory, and occupational —calls for structured post-ICU follow-up consistent with current recommendations for the management of post-intensive care syndrome. Even when patients survive the acute phase, the disease leaves a long shadow. Recognising this is essential to organizing the audiological, psychological, and social support these patients need to truly recover.
About Université de Reims Champagne-Ardenne/CHU de Reims
Université de Reims Champagne-Ardenne (URCA) and its affiliated University Hospital (CHU de Reims) host the Cardiovir research unit (UMRS 1320), which investigates cardiovascular and infectious diseases. The medical faculty and the Medical Intensive Care Unit at CHU de Reims have a long-standing research programme in community-acquired infections and critical care medicine, and have contributed to several major French and European multicenter cohort studies, including the COMBAT cohort on which the present work is based.
Website: www.univ-reims.fr - www.chu-reims.fr
About Hôpital Européen Georges Pompidou (AP-HP)
Hôpital Européen Georges Pompidou (HEGP) is a major teaching hospital of the Assistance Publique – Hôpitaux de Paris (AP-HP), the largest public hospital network in Europe. Affiliated with Université Paris Cité, HEGP combines clinical care, teaching and research across critical care, cardiovascular medicine, oncology and infectious diseases. Its Medical Intensive Care Unit is a tertiary referral centre for severe infections, sepsis and complex critical illness.
Website: hopital-europeen-georges-pompidou.aphp.fr
About Dr. Valentin de Villiers de la Noue (University Clinical Instructor – Hospital Resident) from Hôpital Européen Georges Pompidou (AP-HP)
Dr. Valentin de Villiers de la Noue is a University Clinical Instructor – Hospital Resident in intensive care at Hôpital Européen Georges Pompidou (AP-HP, Paris). He completed his medical degree at Université Paris Descartes and his specialty training in intensive care medicine across multiple French university hospitals, including CHU de Reims and Hôpital Cochin. He also holds a Master’s degree in Ethics and Bioethics from Université de Paris, alongside specialized diplomas in metabolic intensive care and the management of immunocompromised patients. He is the author of five peer-reviewed scientific publications, with a research focus on prognostic factors and long-term outcomes in critically ill patients.
ORCID: 0000-0002-1270-1993
Funding information
The COMBAT study was supported by Assistance Publique – Hôpitaux de Paris, the French Ministry of Health, Inserm, the Société de Pathologie Infectieuse de Langue Française (SPILF), and Pfizer Pharmaceutical Company. The study was endorsed by several French professional societies, including the Société de Réanimation de Langue Française and the Société Française d’Anesthésie-Réanimation.
Journal of Intensive Medicine
Observational study
People
Prognostic factors in ICU patients with community-acquired bacterial meningitis: A post hoc analysis of a multicenter prospective cohort study
13-Jun-2026
Given his role as Journal of Intensive Medicine, Jean-Pierre Quenot had no involvement in the peer-review of this article and has no access to information regarding its peer-review. Full responsibility for the editorial process for this article was delegated to another journal editor. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.